ArticleCancer diagnosis & prognosis
Optimized Prostate Cancer Stage Classification Using XGBoost Based on Racial miRNA Expression.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Prostate cancer has a high mortality rate and shows diagnostic disparities between racial groups, particularly between White and Black populations. This study aimed to develop a prostate cancer stage classification model using the XGBoost algorithm on miRNA expression data with a focus on race-based analysis. Materials and Methods: The data used in this study were obtained from the Genomic Data Commons. The Cancer Genome Atlas through the UCSC Xena Browser, consisting of miRNA expression and patient clinical data. Several feature selection methods were applied, including Student's Results: The results showed that the XGBoost model achieved an accuracy of up to 89% on data from White patients. Additionally, the F1-score shows the results of 92%, these results suggest this model is particularly strong in identifying minority class in this unbalance data. However, when tested on data from Black patients, the accuracy decreased to 72-74%, indicating limitations in cross-race performance. Additionally, Local Interpretable Model-agnostic Explanations (LIME) was implemented to identify the gene features that contributed most significantly to the model's predictions. Conclusion: The study demonstrates that XGBoost, combined with race-specific feature selection and hyperparameter tuning, can accurately detect prostate cancer with high performance. These findings highlight the potential of XGBoost for improving prostate cancer detection while also emphasizing the importance of considering race-specific differences in machine learning models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.